Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $6.00.

Separately, Citigroup began coverage on shares of Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 price target for the company.

Hedge Funds Weigh In On Mersana Therapeutics

A number of large investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. lifted its holdings in Mersana Therapeutics by 104.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 993,046 shares of the company’s stock worth $1,877,000 after buying an additional 507,453 shares during the period. XTX Topco Ltd lifted its stake in Mersana Therapeutics by 186.0% in the third quarter. XTX Topco Ltd now owns 347,255 shares of the company’s stock worth $656,000 after acquiring an additional 225,823 shares during the period. US Bancorp DE bought a new stake in Mersana Therapeutics in the third quarter valued at $31,000. Federated Hermes Inc. increased its position in Mersana Therapeutics by 105,301.7% during the 2nd quarter. Federated Hermes Inc. now owns 185,507 shares of the company’s stock valued at $373,000 after purchasing an additional 185,331 shares during the period. Finally, Exchange Traded Concepts LLC increased its position in Mersana Therapeutics by 95.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 85,006 shares of the company’s stock valued at $161,000 after purchasing an additional 41,586 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.

Mersana Therapeutics Stock Up 5.6 %

MRSN stock opened at $1.50 on Friday. The business’s fifty day moving average price is $2.12 and its two-hundred day moving average price is $1.94. The stock has a market capitalization of $185.30 million, a price-to-earnings ratio of -2.46 and a beta of 1.40. Mersana Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $6.28. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35.

Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.08. The company had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $7.53 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The business’s revenue for the quarter was up 63.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.35) EPS. On average, equities analysts anticipate that Mersana Therapeutics will post -0.61 earnings per share for the current year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.